Ahmad Mohammad Abdo Kheder Shaddad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ahmad Mohammad Abdo Kheder Shaddad has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Aliaë Abd Rabou Mohamed Hussein
Department of Chest Diseases, Assiut University, Assiut, Egypt
8 shared publications - Maiada K. Hashem
Chest Department, Faculty of Medicine, Assiut University, Assiut, Egypt
5 shared publications - Waleed Gamal Elddin Khaleel
Chest Department, Faculty of Medicine, Assiut University, Assiut, Egypt
4 shared publications Esraa A. Talaat
Department of Rheumatology, Rehabilitation and Physical Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt
2 shared publications- Maha Ahmed Okasha
Assiut Police Hospital
2 shared publications Sara Farrag
Department of Rheumatology, Rehabilitation and Physical Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt
2 shared publications
Latest Publications
- Open Access
- 22 February 2024
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 51 (1) , 1-11
Sleep quality, anxiety, depression, and quality of life in rheumatoid arthritis patients and impact of disease activity
Background: Rheumatoid arthritis (RA) is an autoimmune lifelong disease. Systemic manifestations represent a significant aspect of the disease burden. This study aimed to assess sleep quality and psychosocial aspects among RA patients and the impact of disease duration and activity. Results: The mean age for included RA patients was 50.00 ± 9.37 years. The median disease duration was 9.50 (Interquartile range (IQR)=5–15) years and 90% of patients were females. Disease activity score 28 was 4.65 ± 1.66. Anxiety and depression were significantly higher among RA participants. Regarding sleep quality assessment, RA group had significantly higher levels of insomnia than the control group (Insomnia Severity Index median (IQR) was 4.5 (0–15) versus 1 (0–3); p value = 0.013) and daytime sleepiness (Epworth Sleepiness Scale median (IQR) was 4 (1–11.25) versus 1 (0–3); p value = 0.002). RA patients showed significantly higher values of Pittsburgh Sleep Quality Index components as well as the global score indicating poor sleep quality. The 36-item short-form health survey domains, representing physical and mental health, were significantly lower among RA cases versus control subjects. Higher disease activity was positively correlated with anxiety, depression, insomnia, sleep quality, sleep efficiency, and daytime dysfunction, while negatively correlated with all domains of the 36-item short-form health survey. Conclusions: RA patients have increased anxiety and depression levels in addition to poor sleep quality. High disease activity is linked to increased anxiety and depression levels, impaired quality of life, and poor sleep quality.
- 22 February 2024
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 51 (1) , 1-11
Open AccessSleep quality, anxiety, depression, and quality of life in rheumatoid arthritis patients and impact of disease activity
Background: Rheumatoid arthritis (RA) is an autoimmune lifelong disease. Systemic manifestations represent a significant aspect of the disease burden. This study aimed to assess sleep quality and psychosocial aspects among RA patients and the impact of disease duration and activity. Results: The mean age for included RA patients was 50.00 ± 9.37 years. The median disease duration was 9.50 (Interquartile range (IQR)=5–15) years and 90% of patients were females. Disease activity score 28 was 4.65 ± 1.66. Anxiety and depression were significantly higher among RA participants. Regarding sleep quality assessment, RA group had significantly higher levels of insomnia than the control group (Insomnia Severity Index median (IQR) was 4.5 (0–15) versus 1 (0–3); p value = 0.013) and daytime sleepiness (Epworth Sleepiness Scale median (IQR) was 4 (1–11.25) versus 1 (0–3); p value = 0.002). RA patients showed significantly higher values of Pittsburgh Sleep Quality Index components as well as the global score indicating poor sleep quality. The 36-item short-form health survey domains, representing physical and mental health, were significantly lower among RA cases versus control subjects. Higher disease activity was positively correlated with anxiety, depression, insomnia, sleep quality, sleep efficiency, and daytime dysfunction, while negatively correlated with all domains of the 36-item short-form health survey. Conclusions: RA patients have increased anxiety and depression levels in addition to poor sleep quality. High disease activity is linked to increased anxiety and depression levels, impaired quality of life, and poor sleep quality.
- Open Access
- 26 July 2023
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 17 (1) , 1-9
Cognitive impact on patients with COVID-19 infection
Background: SARS‐COV‐2 infection reframed medical knowledge in many aspects, yet there is still a lot to be discovered. Coronavirus disease 19 (COVID-19) can cause neuropsychiatric, psychological, and psychosocial impairments. Literature regarding the cognitive impact of COVID-19 is still limited. This study aims to evaluate cognitive function, anxiety, and depression among patients with coronavirus disease 19. Methods: Sixty COVID-19 patients were recruited and sub-grouped according to the site of care into three groups, home isolation, ward, and RICU, and compared with 60 matched control participants. Entire clinical history, O2 saturation, mini-mental state examination (MMSE), Hamilton’s anxiety (HAM-A), and depression rating scales (HAM-D) were assessed. Results: MMSE showed significantly lowest results for the ICU group, with a value of 21.65 ± 3.52. Anxiety levels were the highest for the ICU group, with a highly significant difference vs. the home isolation group (42.45 ± 4.85 vs. 27.05 ± 9.52; p< 0.001). Depression values assessed showed a highly significant difference in intergroup comparison (44.8 ± 6.64 vs. 28.7 ± 7.54 vs. 31.25 ± 8.89; p<0.001, for ICU vs. ward vs. home group, respectively). MMSE revealed a significant negative correlation with age and education level, anxiety level had significant negative correlations with severity of illness and male gender, and depression level had highly significant negative correlations with severity of illness and male gender. Conclusion: Both cognitive and neuropsychiatric symptoms were affected in COVID-19 cases, especially in ICU-admitted patients. The impact of these disorders was significant in older age, lower oxygen saturation, and severe disease. Trial registration: ClinicalTrials.gov. NCT05293561. Registered on March 24, 2022.
- 26 July 2023
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 17 (1) , 1-9
Open AccessCognitive impact on patients with COVID-19 infection
Background: SARS‐COV‐2 infection reframed medical knowledge in many aspects, yet there is still a lot to be discovered. Coronavirus disease 19 (COVID-19) can cause neuropsychiatric, psychological, and psychosocial impairments. Literature regarding the cognitive impact of COVID-19 is still limited. This study aims to evaluate cognitive function, anxiety, and depression among patients with coronavirus disease 19. Methods: Sixty COVID-19 patients were recruited and sub-grouped according to the site of care into three groups, home isolation, ward, and RICU, and compared with 60 matched control participants. Entire clinical history, O2 saturation, mini-mental state examination (MMSE), Hamilton’s anxiety (HAM-A), and depression rating scales (HAM-D) were assessed. Results: MMSE showed significantly lowest results for the ICU group, with a value of 21.65 ± 3.52. Anxiety levels were the highest for the ICU group, with a highly significant difference vs. the home isolation group (42.45 ± 4.85 vs. 27.05 ± 9.52; p< 0.001). Depression values assessed showed a highly significant difference in intergroup comparison (44.8 ± 6.64 vs. 28.7 ± 7.54 vs. 31.25 ± 8.89; p<0.001, for ICU vs. ward vs. home group, respectively). MMSE revealed a significant negative correlation with age and education level, anxiety level had significant negative correlations with severity of illness and male gender, and depression level had highly significant negative correlations with severity of illness and male gender. Conclusion: Both cognitive and neuropsychiatric symptoms were affected in COVID-19 cases, especially in ICU-admitted patients. The impact of these disorders was significant in older age, lower oxygen saturation, and severe disease. Trial registration: ClinicalTrials.gov. NCT05293561. Registered on March 24, 2022.
- Open Access
- 17 May 2023
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 17 (1) , 1-10
Assessment of sleep quality, anxiety, depression, and quality of life in Behçet’s disease
Background: Behçet’s disease (BD) is a multi-organ disease with different systemic manifestations. While rare in the United States and Europe, it is more common in the Middle East and Asia. BD is one of the commonest encountered vasculitis in Egypt. This study aims to evaluate BD patients' sleep patterns, quality of life, and psychological aspects. Methods: Patients suffering from Behçet’s disease (thirty patients) and 30 matched age and sex-healthy control participants were recruited in our study. The assessment included the entire clinical history and laboratory investigations, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and Oxygen saturation level. Evaluation of sleep quality and presence of sleep-disordered breathing was done using the Pittsburgh Sleep Quality Index (PSQI), Insomnia severity index (ISI), and Epworth sleepiness scale (ESS). Hamilton’s anxiety (HAM-A) and depression rating scales (HAM-D) were used for psychological assessment. The Short Form 36 Quality Of Life Scale (SF-36 QOL) assessed participants' quality of life. Results: Behçet’s disease patients suffered significantly higher levels of anxiety and depression compared to the control group. The prevalence of insomnia and daytime sleepiness was significantly higher among BD patients. All components of PSQI, including the global score, were significantly higher among the BD group. Physical functioning, role limitation due to physical health, and emotional problems; also, general health indices were significantly lower for the BD group. Patients with active BD showed significantly higher levels of anxiety, depression, insomnia, day time dysfunction and significantly lower all domains of the SF-36 QOL Scale. Conclusions: BD is associated with low sleep quality and high levels of anxiety and depression. Disease activity directly impacts anxiety, depression levels, lower sleep quality, and lower quality of life among BD patients. Trial registration: ClinicalTrials.gov. NCT05142995. Registered November 20, 2021.
- 17 May 2023
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 17 (1) , 1-10
Open AccessAssessment of sleep quality, anxiety, depression, and quality of life in Behçet’s disease
Background: Behçet’s disease (BD) is a multi-organ disease with different systemic manifestations. While rare in the United States and Europe, it is more common in the Middle East and Asia. BD is one of the commonest encountered vasculitis in Egypt. This study aims to evaluate BD patients' sleep patterns, quality of life, and psychological aspects. Methods: Patients suffering from Behçet’s disease (thirty patients) and 30 matched age and sex-healthy control participants were recruited in our study. The assessment included the entire clinical history and laboratory investigations, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and Oxygen saturation level. Evaluation of sleep quality and presence of sleep-disordered breathing was done using the Pittsburgh Sleep Quality Index (PSQI), Insomnia severity index (ISI), and Epworth sleepiness scale (ESS). Hamilton’s anxiety (HAM-A) and depression rating scales (HAM-D) were used for psychological assessment. The Short Form 36 Quality Of Life Scale (SF-36 QOL) assessed participants' quality of life. Results: Behçet’s disease patients suffered significantly higher levels of anxiety and depression compared to the control group. The prevalence of insomnia and daytime sleepiness was significantly higher among BD patients. All components of PSQI, including the global score, were significantly higher among the BD group. Physical functioning, role limitation due to physical health, and emotional problems; also, general health indices were significantly lower for the BD group. Patients with active BD showed significantly higher levels of anxiety, depression, insomnia, day time dysfunction and significantly lower all domains of the SF-36 QOL Scale. Conclusions: BD is associated with low sleep quality and high levels of anxiety and depression. Disease activity directly impacts anxiety, depression levels, lower sleep quality, and lower quality of life among BD patients. Trial registration: ClinicalTrials.gov. NCT05142995. Registered November 20, 2021.
- Open Access
- 10 May 2023
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 17 (1) , 1-2
Response to editor’s letter
- 10 May 2023
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 17 (1) , 1-2
Open AccessResponse to editor’s letter
- Open Access
- 21 April 2023
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 17 (1) , 1-8
Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt
Background: Infection breakthrough after COVID-19 vaccination is a point of conflict in current literature not only because of the estimation of the potential hazards and symptoms severity but also due to establishing a vaccination policy and measuring the extent of immunity after vaccination in addition to the waning of the humoral immunity over time. To our knowledge, this is the first study to stratify the risk of post-COVID-19 vaccination breakthroughs in Upper Egypt. Methods: In this cross-sectional observational study, we enrolled 369 vaccinated patients registered in our facility either admitted or in out-patient clinic. Patients were interviewed and any proven history of COVID-19 infection after vaccination was recorded. Results: In the current study, 18.97% (70 patients) of the 369 subjects enrolled in the study had COVID-19breakthrough infection. Students were the high-risk group representing 18.6% of the study subjects. Hypertension, diabetes, and cardiac disease were the most comorbidities associated with a prevalence of 15.7%, 8.6%, and 4.3% respectively. Prior to COVID-19, confirmed infection was present in 42.9% of the study group. Fever, headache, myalgia, and cough were among the most common symptoms of the post-COVID vaccination breakthrough with a prevalence of 90%, 75.7%, 84.3%, and 74.3% respectively. Conclusion: Breakthrough infection after COVID-19 vaccination is not uncommon. Most cases are mild and don’t require hospitalization. All types of vaccines tested in the current study offer adequate immunity and guard against severe COVID-19 infection. We encourage the current global policy of full vaccination. Trial registration: ClinicalTrials.gov. NCT05033834. Registered September 5, 2021. COVID-19 Infection in After Vaccination-Full Text View-ClinicalTrials.gov.
- 21 April 2023
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 17 (1) , 1-8
Open AccessPrevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt
Background: Infection breakthrough after COVID-19 vaccination is a point of conflict in current literature not only because of the estimation of the potential hazards and symptoms severity but also due to establishing a vaccination policy and measuring the extent of immunity after vaccination in addition to the waning of the humoral immunity over time. To our knowledge, this is the first study to stratify the risk of post-COVID-19 vaccination breakthroughs in Upper Egypt. Methods: In this cross-sectional observational study, we enrolled 369 vaccinated patients registered in our facility either admitted or in out-patient clinic. Patients were interviewed and any proven history of COVID-19 infection after vaccination was recorded. Results: In the current study, 18.97% (70 patients) of the 369 subjects enrolled in the study had COVID-19breakthrough infection. Students were the high-risk group representing 18.6% of the study subjects. Hypertension, diabetes, and cardiac disease were the most comorbidities associated with a prevalence of 15.7%, 8.6%, and 4.3% respectively. Prior to COVID-19, confirmed infection was present in 42.9% of the study group. Fever, headache, myalgia, and cough were among the most common symptoms of the post-COVID vaccination breakthrough with a prevalence of 90%, 75.7%, 84.3%, and 74.3% respectively. Conclusion: Breakthrough infection after COVID-19 vaccination is not uncommon. Most cases are mild and don’t require hospitalization. All types of vaccines tested in the current study offer adequate immunity and guard against severe COVID-19 infection. We encourage the current global policy of full vaccination. Trial registration: ClinicalTrials.gov. NCT05033834. Registered September 5, 2021. COVID-19 Infection in After Vaccination-Full Text View-ClinicalTrials.gov.
- Open Access
- 10 March 2023
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 17 (1) , 1-8
Short-term evaluation of motor and sensory nerve conduction parameters in COVID-19-associated peripheral neuropathy patients
Background: Severe acute respiratory syndrome coronavirus 2 (SARS‐COV‐2) is mostly associated with upper and lower respiratory tract manifestations. However, coronavirus disease 19 (COVID-19) can result in a wide range of other systemic symptomatology, including neuropsychiatric, psychological, and psychosocial impairments. Literature regarding neurological compromise, including neuropathy and sensory and motor affection associated with COVID-19, is still limited. This study aims to evaluate the sensory, motor neuropathy, and secondary neurological impairment among patients with mild to moderate coronavirus disease associated with peripheral neuropathy within 1 month. Methods: Forty participants, including 20 mild to moderate COVID-19 patients with peripheral neuropathy and 20 age and gender-matched healthy volunteers, were recruited in this case/control study. Laboratory evaluation focused on C-reactive protein (CRP) and D-dimer levels. Oxygen saturation for all participants was recorded. The neurophysiological study included motor nerve study, sensory nerve study, and F wave study for upper and lower limbs were done. Results: The two groups were similar regarding baseline data. Neurological symptoms’ onset in the COVID-19 group ranged from 4 to 24 days. Levels of CRP and D-dimer levels were significantly higher in patients versus the control group. Motor nerve conduction (MNC) amplitude and latency for the median nerve were significantly compromised among the COVID-19 group. The MNC latency and F wave latency for the posterior tibial nerve were significantly higher in the COVID-19 group. The CRP and D-dimer levels were associated with a significant positive correlation with a latency of median nerve MNC, sensory nerve conduction (SNC), and f-wave; latency of MNC and F wave of the posterior tibial nerve; and SNC latency for sural nerve. Conclusion: neurological involvement can occur in mild to moderate cases of SARS-COV-2 infection and add to the burden of the disease. Neurological symptoms in the course of COVID-19 disease should be interpreted cautiously, and appropriate diagnosis, including nerve conduction studies and management, should be considered. Trial registration: ClinicalTrials.gov. NCT05721040.
- 10 March 2023
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 17 (1) , 1-8
Open AccessShort-term evaluation of motor and sensory nerve conduction parameters in COVID-19-associated peripheral neuropathy patients
Background: Severe acute respiratory syndrome coronavirus 2 (SARS‐COV‐2) is mostly associated with upper and lower respiratory tract manifestations. However, coronavirus disease 19 (COVID-19) can result in a wide range of other systemic symptomatology, including neuropsychiatric, psychological, and psychosocial impairments. Literature regarding neurological compromise, including neuropathy and sensory and motor affection associated with COVID-19, is still limited. This study aims to evaluate the sensory, motor neuropathy, and secondary neurological impairment among patients with mild to moderate coronavirus disease associated with peripheral neuropathy within 1 month. Methods: Forty participants, including 20 mild to moderate COVID-19 patients with peripheral neuropathy and 20 age and gender-matched healthy volunteers, were recruited in this case/control study. Laboratory evaluation focused on C-reactive protein (CRP) and D-dimer levels. Oxygen saturation for all participants was recorded. The neurophysiological study included motor nerve study, sensory nerve study, and F wave study for upper and lower limbs were done. Results: The two groups were similar regarding baseline data. Neurological symptoms’ onset in the COVID-19 group ranged from 4 to 24 days. Levels of CRP and D-dimer levels were significantly higher in patients versus the control group. Motor nerve conduction (MNC) amplitude and latency for the median nerve were significantly compromised among the COVID-19 group. The MNC latency and F wave latency for the posterior tibial nerve were significantly higher in the COVID-19 group. The CRP and D-dimer levels were associated with a significant positive correlation with a latency of median nerve MNC, sensory nerve conduction (SNC), and f-wave; latency of MNC and F wave of the posterior tibial nerve; and SNC latency for sural nerve. Conclusion: neurological involvement can occur in mild to moderate cases of SARS-COV-2 infection and add to the burden of the disease. Neurological symptoms in the course of COVID-19 disease should be interpreted cautiously, and appropriate diagnosis, including nerve conduction studies and management, should be considered. Trial registration: ClinicalTrials.gov. NCT05721040.
- Open Access
- 6 February 2023
- Published by Springer Nature in Research Square
Clinical characteristics and outcome of COVID-19 patients with non cystic fibrosis bronchiectasis
Introduction: Non cystic fibrosis bronchiectasis is an uncommon respiratory disease and was described as a rare imaging feature of COVID-19 infection, but no published studies are reporting the clinical course and outcome of coexisting COVID-19 and confirmed cases of bronchiectasis during acute stage. The aim of this study was to assess the course and outcome of COVID-19 infection in bronchiectasis patient. Patients and methods: A cross-sectional study including 411 COVID-19 confirmed cases that were examined by high resolution computed tomography of the chest during acute phase (4 weeks) of the infection. They were divided into Group A: COVID-19 patients without bronchiectasis (n=400) and Group B included COVID-19 patients with preexisting clinical and radiologic evidence of bronchiectasis (n=11). Results: Patients with preexisting chronic bronchiectasis (Grup B) had significantly higher cough score, frequency of colored sputum and mMRC score, respiratory distress (p< 0.001) and respiratory failure (p= 0.02) than those without bronchiectasis. They also had the higher frequency of ICU’s admission (p< 0.001), need to non-invasive (p= 0.01), and invasive mechanical ventilation (p= <0.001), duration of mechanical ventilation, ICU’s stay and overall hospital stay (p<0.001). Death rate was also statistically significantly higher in Group B compared to Group A (p= 0.04). Conclusion: Concomitant bronchiectasis increases disease burden in COVID-19 patients. It increased the severity of presenting symptoms and was associated with worse clinical outcome (ICU admission, need for ventilator support) and mortality.
- 6 February 2023
- Published by Springer Nature in Research Square
Open AccessClinical characteristics and outcome of COVID-19 patients with non cystic fibrosis bronchiectasis
Introduction: Non cystic fibrosis bronchiectasis is an uncommon respiratory disease and was described as a rare imaging feature of COVID-19 infection, but no published studies are reporting the clinical course and outcome of coexisting COVID-19 and confirmed cases of bronchiectasis during acute stage. The aim of this study was to assess the course and outcome of COVID-19 infection in bronchiectasis patient. Patients and methods: A cross-sectional study including 411 COVID-19 confirmed cases that were examined by high resolution computed tomography of the chest during acute phase (4 weeks) of the infection. They were divided into Group A: COVID-19 patients without bronchiectasis (n=400) and Group B included COVID-19 patients with preexisting clinical and radiologic evidence of bronchiectasis (n=11). Results: Patients with preexisting chronic bronchiectasis (Grup B) had significantly higher cough score, frequency of colored sputum and mMRC score, respiratory distress (p< 0.001) and respiratory failure (p= 0.02) than those without bronchiectasis. They also had the higher frequency of ICU’s admission (p< 0.001), need to non-invasive (p= 0.01), and invasive mechanical ventilation (p= <0.001), duration of mechanical ventilation, ICU’s stay and overall hospital stay (p<0.001). Death rate was also statistically significantly higher in Group B compared to Group A (p= 0.04). Conclusion: Concomitant bronchiectasis increases disease burden in COVID-19 patients. It increased the severity of presenting symptoms and was associated with worse clinical outcome (ICU admission, need for ventilator support) and mortality.
- Open Access
- 18 November 2022
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 16 (1) , 1-7
Prevalence and early outcome of bronchiectasis as an atypical presentation in COVID-19 patients
Introduction: Bronchiectasis was considered as an uncommon radiological feature of corona virus disease 2019 (COVID-19) infection. The clinical course and outcome of COVID-19 bronchiectasis overlap is still a point for research. The aim of this study was to evaluate the prevalence, course, and outcome of bronchiectasis as an atypical presentation of COVID-19 infection. Methods: A cross-sectional study has been conducted from July 2021 to February 2022 and included 425 COVID-19 swab-positive patients who were examined by high resolution computed tomography of the chest during acute phase (4 weeks) of the infection. Results: Fourteen (3.3%) patients newly developed bronchiectasis-de novo. Patients with de novo bronchiectasis had significantly higher cough score, frequency of colored sputum and mMRC score, respiratory distress (p < 0.001) and respiratory failure (p = 0.02) than patients with no bronchiectasis. They also had the higher frequency of ICU’s admission (p = 0.02), need to non-invasive (p = 0.01), and invasive mechanical ventilation (p = < 0.001), duration of mechanical ventilation, ICU’s stay and overall hospital stay (p < 0.001). As for the outcome, death rate was also statistically significantly higher among those with De novo bronchiectasis than those without bronchiectasis (p = 0.04). Conclusion: Bronchiectasis is an uncommon presentation among COVID-19 patients. However, bronchiectasis increases disease burden in COVID-19 patients. It may have a negative impact on the outcome. Trial registration: ClinicalTrials.gov. NCT04910113. Registered June 2, 2021.
- 18 November 2022
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 16 (1) , 1-7
Open AccessPrevalence and early outcome of bronchiectasis as an atypical presentation in COVID-19 patients
Introduction: Bronchiectasis was considered as an uncommon radiological feature of corona virus disease 2019 (COVID-19) infection. The clinical course and outcome of COVID-19 bronchiectasis overlap is still a point for research. The aim of this study was to evaluate the prevalence, course, and outcome of bronchiectasis as an atypical presentation of COVID-19 infection. Methods: A cross-sectional study has been conducted from July 2021 to February 2022 and included 425 COVID-19 swab-positive patients who were examined by high resolution computed tomography of the chest during acute phase (4 weeks) of the infection. Results: Fourteen (3.3%) patients newly developed bronchiectasis-de novo. Patients with de novo bronchiectasis had significantly higher cough score, frequency of colored sputum and mMRC score, respiratory distress (p < 0.001) and respiratory failure (p = 0.02) than patients with no bronchiectasis. They also had the higher frequency of ICU’s admission (p = 0.02), need to non-invasive (p = 0.01), and invasive mechanical ventilation (p = < 0.001), duration of mechanical ventilation, ICU’s stay and overall hospital stay (p < 0.001). As for the outcome, death rate was also statistically significantly higher among those with De novo bronchiectasis than those without bronchiectasis (p = 0.04). Conclusion: Bronchiectasis is an uncommon presentation among COVID-19 patients. However, bronchiectasis increases disease burden in COVID-19 patients. It may have a negative impact on the outcome. Trial registration: ClinicalTrials.gov. NCT04910113. Registered June 2, 2021.
- Open Access
- 18 March 2022
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 16 (1) , 1-10
The clinical and functional characteristics of bronchiectasis among tuberculosis patients in Upper Egypt: a single-center study
Background: Tuberculosis (TB) is considered one of the most common causes of bronchiectasis. Bronchiectasis increases clinical and financial burden of patients with TB. Here, we aim to assess the prevalence of bronchiectasis and its characteristics in patients with TB.Results: Over 1 year duration, 85 patients with confirmed TB were enrolled in the study. Those patients were clinically, laboratory, and radiologically evaluated. Any patient with other chest diseases was excluded from the study. Out of those patients, 19/85 (22.4%) patients had bronchiectasis. It was found that patients with bronchiectasis had higher frequency of urban residence, current cigarette or goza smoking, and diabetes mellitus. Hemoptysis and expectoration were the most frequent symptoms. Pulmonary function tests were significantly impaired in patients with bronchiectasis. Disease burden was significantly higher among bronchiectasis group in form of frequent hospitalization, longer hospital stay, and need of oxygen therapy.Conclusion: Bronchiectasis is not uncommon among TB patients. Co-existence of bronchiectasis with TB has distinctive clinical, and functional characteristics that increase the burden of the diseases in the form of prolonged hospital stay and higher utilization of antibiotics and oxygen therapy. Smoking in tuberculous patients may is significantly associated with bronchiectasis.
- 18 March 2022
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 16 (1) , 1-10
Open AccessThe clinical and functional characteristics of bronchiectasis among tuberculosis patients in Upper Egypt: a single-center study
Background: Tuberculosis (TB) is considered one of the most common causes of bronchiectasis. Bronchiectasis increases clinical and financial burden of patients with TB. Here, we aim to assess the prevalence of bronchiectasis and its characteristics in patients with TB.Results: Over 1 year duration, 85 patients with confirmed TB were enrolled in the study. Those patients were clinically, laboratory, and radiologically evaluated. Any patient with other chest diseases was excluded from the study. Out of those patients, 19/85 (22.4%) patients had bronchiectasis. It was found that patients with bronchiectasis had higher frequency of urban residence, current cigarette or goza smoking, and diabetes mellitus. Hemoptysis and expectoration were the most frequent symptoms. Pulmonary function tests were significantly impaired in patients with bronchiectasis. Disease burden was significantly higher among bronchiectasis group in form of frequent hospitalization, longer hospital stay, and need of oxygen therapy.Conclusion: Bronchiectasis is not uncommon among TB patients. Co-existence of bronchiectasis with TB has distinctive clinical, and functional characteristics that increase the burden of the diseases in the form of prolonged hospital stay and higher utilization of antibiotics and oxygen therapy. Smoking in tuberculous patients may is significantly associated with bronchiectasis.
- Open Access
- 18 March 2022
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 16 (1) , 1-7
The burden of COVID-19 pandemic on tuberculosis detection: a single-center study
Background: Since being declared a global pandemic, Coronavirus disease 2019 (COVID-19) took over healthcare providers and researchers’ interest. However, other epidemic diseases, including tuberculosis (TB), are still a health issue that aggravate under the umbrella of health facilities exhaustion. This study aims to evaluate the impact of the COVID-19 pandemic on tuberculosis management. Methods: A retrospective analysis of the quarterly reports issued by a tuberculosis management unit from 2017 to June 2021, including data of 12 subunits. The changes in pulmonary and extrapulmonary tuberculosis incidence trends (new + relapsed cases) throughout the 4 years were reported. The quarterly changed percentages in cases numbers along 2020 and first half of 2021 was compared with that of the same periods in 2019. Results: Incidence of extrapulmonary tuberculosis was higher than pulmonary tuberculosis throughout the 4 year study periods (7.69 vs. 4.49, 9.44 vs. 4.33, 7.75 vs. 3.58, and 7.82 vs. 2.94/100.000 population, respectively) with a noticeable decline in the incidence of pulmonary TB during 2020. The second quarter of 2020 showed the lowest tuberculosis incidence rate with a 41.6% decline in the total number of diagnosed cases while 2nd quarter of 2021 showed 21.2% decline. During 2020, only 4 cases of multidrug-resistant TB were reported (compared to an average of 8 cases of MDR-TB yearly before the COVID-19 era). Conclusion: There was a noticeable drop in tuberculosis case detection during the COVID-19 pandemic. The lockdown, started in Egypt by the end of March 2020, could contribute to the marked drop in the second quarter. However, a steady partial decline was continued during the first half of 2021, which foretells a growing problem.
- 18 March 2022
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 16 (1) , 1-7
Open AccessThe burden of COVID-19 pandemic on tuberculosis detection: a single-center study
Background: Since being declared a global pandemic, Coronavirus disease 2019 (COVID-19) took over healthcare providers and researchers’ interest. However, other epidemic diseases, including tuberculosis (TB), are still a health issue that aggravate under the umbrella of health facilities exhaustion. This study aims to evaluate the impact of the COVID-19 pandemic on tuberculosis management. Methods: A retrospective analysis of the quarterly reports issued by a tuberculosis management unit from 2017 to June 2021, including data of 12 subunits. The changes in pulmonary and extrapulmonary tuberculosis incidence trends (new + relapsed cases) throughout the 4 years were reported. The quarterly changed percentages in cases numbers along 2020 and first half of 2021 was compared with that of the same periods in 2019. Results: Incidence of extrapulmonary tuberculosis was higher than pulmonary tuberculosis throughout the 4 year study periods (7.69 vs. 4.49, 9.44 vs. 4.33, 7.75 vs. 3.58, and 7.82 vs. 2.94/100.000 population, respectively) with a noticeable decline in the incidence of pulmonary TB during 2020. The second quarter of 2020 showed the lowest tuberculosis incidence rate with a 41.6% decline in the total number of diagnosed cases while 2nd quarter of 2021 showed 21.2% decline. During 2020, only 4 cases of multidrug-resistant TB were reported (compared to an average of 8 cases of MDR-TB yearly before the COVID-19 era). Conclusion: There was a noticeable drop in tuberculosis case detection during the COVID-19 pandemic. The lockdown, started in Egypt by the end of March 2020, could contribute to the marked drop in the second quarter. However, a steady partial decline was continued during the first half of 2021, which foretells a growing problem.